Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

NEW YORK, December 30, 2025, 15:14 ET — Regular session Shares of TIC Solutions, Inc. (TIC) fell about 3.5% to $10.02 in afternoon trading on Tuesday, underperforming a largely steady U.S. equity market. The stock last closed at $10.38. The decline came in holiday-thin trade as investors recalibrated rate expectations after the Federal Reserve’s December-meeting minutes hit the tape. “At the end of the day, solid corporate profits can make up for a lot of sins,” said Ryan Detrick, chief market strategist at Carson Group. Reuters The slide matters for TIC because investors have been focused on execution rather than
30 December 2025
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
30 December 2025
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Caris Life Sciences shares fell 1.8% to $27.44 by 2:41 p.m. ET Tuesday, underperforming biotech peers as sector benchmarks declined. The drop followed recent attention on Caris’ Genentech partnership, which includes $25 million upfront and up to $1.1 billion in potential milestones. The S&P 500 and Nasdaq were flat. Investors are watching Caris’ test volumes and revenue guidance.
30 December 2025
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management shares dropped 3.1% to $163.85 Tuesday afternoon, underperforming rivals as fresh Federal Reserve minutes showed policymakers split on future rate cuts. A Reuters column noted shrinking yield premiums in private credit, a core Ares business, as public markets regain ground. About 966,000 Ares shares traded, with the stock hitting a low of $163.49. Blackstone was flat; Apollo, KKR, and Carlyle edged down less than 1%.
30 December 2025
··
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Karman Holdings shares fell 3.6% to $74.81 in New York afternoon trading Tuesday, underperforming the broader market after a $258.7 million outflow from the SPDR S&P Aerospace & Defense ETF. The stock touched a session low of $74.21, with about 465,000 shares traded. Investors are watching for signs of stabilization ahead of the company’s next quarterly update.
30 December 2025
··
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
1 … 287 288 289 290 291 … 535

Stock Market Today

China Construction Bank Class A stock ticks up at Friday close as China data looms

China Construction Bank Class A stock ticks up at Friday close as China data looms

7 February 2026
China Construction Bank Class A shares closed up 0.11% at 8.84 yuan in Shanghai on Friday, with around 100 million shares traded. The Shanghai Composite slipped 0.25%. Investors are watching for January inflation data on Feb. 11 and credit figures on Feb. 13 for policy signals. Premier Li Qiang called for early fiscal support to meet economic targets, state media reported.
PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

7 February 2026
PetroChina A-shares rose 2.3% to 10.77 yuan Friday, outperforming the Shanghai Composite, which fell 0.25%. Crude prices rebounded, with Brent settling at $68.05 a barrel, as traders tracked U.S.-Iran talks and new EU sanctions proposals. About 198.5 million PetroChina shares traded in the session. Investors await the company’s next earnings report later this quarter.
Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Go toTop